Ozempic, also known as semaglutide, is a medication used to improve blood sugar control in adults with type 2 diabetes [1]. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the functions of natural hormones in your body to control blood sugar levels [1].

While Ozempic's primary mechanism of action is related to blood sugar control, there is some evidence to suggest that GLP-1 receptor agonists may have an impact on appetite and food intake [2]. A study published in the journal Diabetes, Obesity and Metabolism found that GLP-1 receptor agonists can lead to a reduction in food intake and body weight [3]. However, this study did not specifically investigate the impact of Ozempic on meal portion preferences.

It is important to note that while GLP-1 receptor agonists may have an impact on appetite and food intake, they are not typically prescribed for the purpose of weight loss [1]. The primary goal of Ozempic is to help manage blood sugar levels in people with type 2 diabetes.

In summary, while there is some evidence to suggest that GLP-1 receptor agonists like Ozempic may have an impact on appetite and food intake, there is no specific evidence to suggest that Ozempic alters meal portion preferences. It is important to speak with a healthcare provider for personalized medical advice.

Sources:

* [1] FDA. (2017). Ozempic (semaglutide) injection, for subcutaneous use. <https://www.fda.gov/media/108130/download>
* [2] Drugs.com. (2021). Ozempic. <https://www.drugs.com/ozempic.html>
* [3] Halford, J. C., & Blundell, J. E. (2012). Glucagon-like peptide-1 receptor agonists: effects on appetite and food intake. Diabetes, Obesity and Metabolism, 14(5), 391-401. <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1463-1326.2011.01531.x>
* [4] DrugPatentWatch.com. (2021). Ozempic (semaglutide) Patents. <https://www.drugpatentwatch.com/drugs/ozempic>